Ocaratuzumab Biosimilar - Research Grade

Human

MS4A1

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human CD20 (2H7) Antibody (ICH1012), Rituximab Biosimilar - Research Grade (ICH4011), Obinutuzumab Biosimilar - Research Grade (ICH4026), Ofatumumab Biosimilar - Research Grade (ICH4027), Veltuzumab Biosimilar - Research Grade (ICH5099), Ublituximab Biosimilar - Research Grade (ICH5297), Ibritumomab Biosimilar - Research Grade (ICH5310), Ocrelizumab Biosimilar - Research Grade (ICH5314), Blontuvetmab Biosimilar - Research Grade (ICH5409), Divozilimab Biosimilar - Research Grade (ICH5483), Epitumomab Biosimilar - Research Grade (ICH5530), Ripertamab Biosimilar - Research Grade (ICH5826), Tositumomab Biosimilar - Research Grade (ICH5937), Zuberitamab Biosimilar - Research Grade (ICH6012)

https://www.imgt.org/mAb-DB/

ICH3002

P11836

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ocaratuzumab, supplied for research use only. Ocaratuzumab is an Fc-engineered humanized IgG1 kappa monoclonal antibody directed against CD20 (encoded by MS4A1), originally developed with enhanced binding affinity and an engineered Fc region intended to potentiate antibody-dependent cell-mediated cytotoxicity (ADCC) relative to first-generation anti-CD20 agents. The research-grade biosimilar reproduces the antigen-binding specificity of the originator, giving investigators a defined, reproducible anti-CD20 reagent for building assays and controls rather than for any clinical or in-vivo human application. It is useful as a benchmarking tool in comparative binding and effector-function studies, as a positive control alongside other anti-CD20 molecules, for characterizing CD20-expressing cell lines and primary B cells, and as a starting point in ADCC or antibody-drug-conjugate development workflows. The material is offered at research grade with low endotoxin (typically under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and can be provided in bulk milligram-to-gram quantities. It is not the clinical drug and is not intended for human or veterinary use. CD20, the product of the MS4A1 gene (UniProt P11836), is a roughly 33-37 kDa non-glycosylated membrane phosphoprotein and a member of the membrane-spanning 4-domains subfamily A. It adopts a four-transmembrane-domain topology with intracellular N- and C-termini and two extracellular loops, the larger of which carries the epitopes recognized by therapeutic anti-CD20 antibodies. CD20 is expressed across most stages of B-cell development, from late pro-B cells through mature and memory B cells, but is absent on early pro-B cells and on terminally differentiated plasma cells. Functionally it is implicated in regulating transmembrane calcium flux, organization of B-cell receptor signaling elements, and control of B-cell activation and proliferation. Because CD20 is highly and selectively expressed on B cells and is not readily internalized or shed after antibody binding, it is a durable surface target for antibody-mediated B-cell depletion and a widely used B-lineage marker.

B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, B-lymphocyte antigen CD20, CD20

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks